相关实验视频

Updated: May 30, 2025

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

通过有效的PI3Kinase向,绕过Nrf2过度活化的头癌中西斯普拉丁耐药性的治疗

P Yadollahi¹, K A McCord², Y Li¹

¹Bobby R. Alford Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX.

bioRxiv : the preprint server for biology

|January 27, 2025

概括

像吉达托利西布这样的PI3K抑制剂可以通过破坏新陈代谢途径来克服头部和部状细胞癌 (HNSCC) 中的西斯普拉丁耐药性. 这提供了一个有前途的策略,使瘤重新敏感化疗和放射治疗,改善治疗耐药HNSCC的结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

头部和部状细胞癌 (HNSCC) 通常会对标准辐射和西斯治疗产生抗性,导致预后不佳.
在HNSCC中,Nrf2通路促进了耐药性,并抑制了抗瘤免疫力.
向药物可以克服耐火性HNSCC的耐药性,特别是与特定的瘤驱动因素,如NOTCH1突变.

研究的目的:

调查酸酸3-激酶抑制剂 (PI3Ki) 在克服HNSCC中Nrf2-介导的西斯普拉丁耐药性的疗效.
评估PI3Ki作为化学辐射耐火性HNSCC的治疗策略.

主要方法:

在实验室中用PI3Ki治疗的对西斯普拉丁耐药HNSCC的转录组,代谢组和信号分析.
在使用免疫缺陷和人性化小鼠的皮下,正管和转移性异种移植模型中进行体内疗效测试.
空间转录学用于分析瘤微环境变化.

主要成果:

在Nrf2-驱动的抗思普拉丁HNSCC中,PI3K通路被激活,是可行的治疗标.
PI3Ki gedatolisib 抑制了增殖,诱导细胞循环停止,并通过促进自和衰老来增强西斯的疗效.
格达托利西布在体内抑制了瘤生长,减少了缺氧,降低了调控性T细胞透,特别是在人性化的模型中.

结论:

PI3K-AKT-mTOR通路对抗西斯普拉丁的HNSCC至关重要,这凸显了PI3Ki.的治疗潜力.
基达托利西布通过代谢调节重新敏感化了对西斯普拉丁耐药的HNSCC,这表明它对抗化学辐射失败的组合疗法具有前途.

关键词:

这就是NRF2的NRF2.这是可解释的.格达托利西布 (Gedatolisib) 是一个头部和部癌症头部和部癌症

更多相关视频

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...